Biotechnology

Allogene Therapeutics

Allogene Therapeutics released FY2026 Q1 earnings on May 13 After-Market EST, actual revenue USD 0 (forecast USD 1.82 K), actual EPS USD -0.18 (forecast USD -0.19)

Allogene Therapeutics Terminates Exclusive Licensing Agreement with Overland Therapeutics

Allogene Therapeutics to release FY2026 Q1 earnings on May 13 After-Market EST, forecast revenue USD 1.82 K, EPS USD -0.19

Healthcare Sector Financing: Luofang Bio, Allogene Therapeutics, etc. Raise a Total of Approximately 2.037 Billion Yuan

Allogene Therapeutics Reports Mid-Term Data on Experimental Blood Cancer Therapy

Allogene Therapeutics Announces Positive Interim Results from cema-cel's Phase II Trial

Allogene Therapeutics released FY2025 earnings on March 12 After-Market EST, actual revenue USD 0 (forecast USD 1.67 K), actual EPS USD -0.8652 (forecast USD -0.9289)

Allogene Therapeutics released FY2025 Q4 earnings on March 12 After-Market EST, actual revenue USD 0 (forecast USD 2 K), actual EPS USD -0.1717 (forecast USD -0.2171)

Allogene Therapeutics to Release FY2025 Q4 Earnings on March 12 After-Market EST, Forecast Revenue USD 2K, EPS USD -0.2164

Oppenheimer and William Blair Analysts Reiterate Buy Rating on Allogene Therapeutics

Allogene Therapeutics released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 0 (forecast USD 1.82 K), actual EPS USD -0.1864 (forecast USD -0.2224)

Allogene Therapeutics released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 0, actual EPS USD -0.7

Allogene Therapeutics to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 1.82 K, EPS USD -0.2224

Analyst Cheng covers healthcare industry and focuses on specific stocks

Allogene Therapeutics released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2326 (forecast USD -0.2752)

Allogene Therapeutics released FY2025 Semi-Annual earnings on August 13 After-Market EST, actual revenue USD 0, actual EPS USD -0.5096

Allogene Therapeutics to Release FY2025 Q2 Earnings on August 13 After-Market (EST), Forecast EPS -0.2752 USD

Allogene Therapeutics Holds Annual Meeting of Stockholders

Allogene Therapeutics Inc. Director Sells Company Stock

Allogene Displays ALLO-316 Phase I Trial Data

OPTIMI HEALTH CORP

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

HCW Biologics

GCL Global

Micware

Silexion Therapeutics

MetaVia

BiomX

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

Vida Global

ALLO

LABU

SBIO

Canaccord Genuity analyst John Newman has maintained a Buy rating on Allogene Therapeutics (ALLO) with a price target of $14.00. Newman, who focuses on the Healthcare sector, has an average return of 3.8% and a 42.42% success rate on his stock recommendations. The analyst consensus for Allogene Therapeutics is a Strong Buy, with a price target consensus of $8.71.

Tip Ranks

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Nuvalent

Delcath

Compass Therapeutics

Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)

IBBQ

Allogene (ALLO) has terminated its exclusive Overland license for cell therapies in several Asian countries, effective May 12, 2026, with no cash payment and equity reduced to approximately 3%. The company reported a 58.3% MRD negativity in its ALPHA3 Phase 2 trial and achieved RMAT designation for ALLO-316. In Q1 2026, Allogene posted a net loss of $42.6M with no revenue, but improved adjusted EPS. The company completed a $187.9M offering, extending its cash runway to 2029, while its stock saw a 5.7% decline in Q1 but a 67.9% increase year-to-date.

TradingView

Invesco Nasdaq Biotechnology ETF

Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity

Earnings Watch

Allogene Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

LABD

Allogene Therapeutics, Inc., a clinical-stage biotechnology company (Nasdaq: ALLO) based in South San Francisco, has scheduled its release of the first quarter financial results for 2026 along with a business update on May 13, 2026. The announcement is set to occur after the market closes, followed by a live audio webcast and conference call at 2 p.m. PT/5 p.m. ET. Allogene focuses on developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease.

Unusual Whales

Direxion S&P Biotech Bear 3X

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

DTIL

Alpenglow Biosciences has launched Summit AI, a multimodal AI platform for quantitative analysis of whole tissue imaging in dermatology. This platform converts complex imaging data into structured spatial readouts while maintaining the original image context. Initially focused on inflammatory skin diseases, Summit AI aims to enhance tissue analysis by providing comprehensive insights into tissue architecture and disease states. It integrates 3D imaging with 2D readouts and includes uncertainty metrics to improve confidence in model outputs, supporting drug development and clinical diagnostics.

MBX Biosciences

Precision Biosciences

iShares US Pharma

VG Health

Ark Genomic Revolution ETF

iShares Global Healthcare

Health Care Select Sector SPDR

Alpenglow Biosciences Introduces Summit AI for Quantitative Analysis of Whole Tissue Imaging in Dermatology

Allogene Therapeutics(ALLO.US)

Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)

Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity

Allogene Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Alpenglow Biosciences Introduces Summit AI for Quantitative Analysis of Whole Tissue Imaging in Dermatology